CompletedNot Applicable

Effect of Modifying Magnesium Concentration in Citrate-enriched Dialysate on Serum Magnesium Levels

Belgium54 participantsStarted 2025-01-28

Plain-language summary

Individuals with ESKD and treated with hemodialysis have a high mortality risk. Associative studies suggest a relationship between serum magnesium concentration and mortality risk. The influence of magnesium concentration on mortality risk is unknown. This pilot study will explore whether altering dialysate magnesium concentration in the presence of citrate will change serum magnesium concentrations.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Written informed consent must be obtained prior to any screening procedures
✓. Clinically stable during two months prior to the study. This will be based upon clinical judgement.
✓. On stable blood pressure medication 4 weeks prior to the study
✓. Dialysis with a K3 dialysate
✓. Adequate double-needle dialysis access (fistula or catheter)
✓. Able to fill questionnaire/symptom score

Exclusion criteria

✕. Predialysis calcium \<1,9mmol/L during baseline
✕. Magnesium predialysis \>1,45mmol/L during baseline
✕. Patient has a history of child C liver cirrhosis
✕. Coronary intervention \<3 months before randomization
✕. Hospitalization \<2 months before randomization
✕. Uncontrolled predialysis hypertension \>160/90mmHg despite 4 antihypertensive drugs
✕. Predialysis blood pressure \<90mmHg during baseline visit
✕. History of dialysis access related problems \<1 month before the randomization

What they're measuring

Proportion predialysis magnesium in target range

Timeframe: 2 weeks

Trial details

NCT IDNCT07565779

SponsorUniversitaire Ziekenhuizen KU Leuven

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-01-15

View on ClinicalTrials.gov More Dialysis; Complications trials